BioMap and Bluepha Announce Strategic Collaboration to Build a Next-Generation AI-Powered Intelligent R&D Platform for Bio-Manufacturing

Recently, BioMap and Beijing Bluepha Microbiology Technology Co., Ltd. announced a strategic partnership. Both parties will fully leverage their respective technological and resource advantages in foundational large models of life sciences and bio-manufacturing processes to jointly build a new generation intelligent R&D platform for the bio-manufacturing field.The platform willAIDriven by a core system of data and models, connecting algorithms, experiments, and process stages to enhance R&D efficiency and validation capabilities, achieving collaborative optimization in cost, quality, and timeline across multiple synthetic biology pipelines.

Over the past decade, bio-manufacturing has gradually become a key force in promoting green and sustainable development. Bio-based materials, due to their complete biodegradability and recyclability, play an important role in replacing petrochemical plastics and reducing carbon emissions. Beijing Bluepha Microbiology Technology Co., Ltd. was founded in2016Year, one of the first synthetic biology platform companies in China,Not only successfully achieved the large-scale industrial production of bio-based materials, and has also made significant progress in agriculture, health product ingredients, and cosmetic ingredients.

In the research and production process of the synthetic biology field, key proteins and industrial enzymes dominate the crucial transformation steps from carbon sources to macromolecular polymers, with the former determining the reaction.“Whether it can happen”, the latter determines the reaction“Whether it can occur stably and efficiently”. However,The transformation of laboratory achievements into industrialization still faces multiple challenges.: In the early pipeline research phase, R&D collaboration is scattered, and knowledge accumulation is fragmented; during the enzyme engineering phase, challenges include low hit rates, large screening scales, high costs, and the difficulty of achieving a balance among critical metrics such as activity, thermal stability, and substrate specificity, leading to long R&D cycles and high implementation difficulty.

BioMap2024Year10Full-modal Bio Large Model Released in [Month] xTrimo V3, to2100Hundreds of millions of parameters refresh the global record, and2025Year4Launches World's First Generative Discovery System Driven by a Large-Scale Life Science Foundation Model in the Month——xTrimoKnowledge Assistant. Relying onxTrimoThe multimodal understanding and generation capabilities, BioMap has built a coverage of information acquisition—Biological Insights—The Whole Process of Intelligent ExperimentAIR&D Platform, Helping Life Science Enterprises Achieve R&D Acceleration and Process Integration Upgrade.

Based on this strategic cooperation, both parties will focus on "data—Model—"Experiment" closed-loop as the driving force, creating an accelerated channel from cognition, design to verification and amplification. As one of the core capabilities of the intelligent R&D platform,xTrimoThe knowledge assistant can uniformly parse multi-source information such as literature, patents, and experimental records, converting dispersed data into traceable and reusable structured knowledge. Through data standardization and knowledge extraction, it provides structured support for the intelligent R&D system of Beijing Bluepha Microbiology Technology Co., Ltd., significantly shortening the cycle for forming solutions.

At the same time, independently developed by BioMapxTrimo AIGP（AI Generated Protein) The platform will serve as the "Protein and Enzyme Intelligent Design Engine" of the intelligent R&D platform, and will be deeply applied in the real R&D and production system of Beijing Bluepha Microbiology Technology Co., Ltd.

xTrimo AIGPHailed by the industry as "capable of producing proteinsChatGPT"，even researchers without programming skills can leverage large models and dozens of protein-related task models, along with supporting software and hardware systems, to carry out innovative protein design research."xTrimo AIGPWill be in sequence—Structure—Based on the joint representation of functions, facingKey Proteins and Industrial EnzymesProvide multi-index performance prediction and ranking, combine rational design with combinatorial mutations to generate high-quality candidates, support multi-objective weighting andParetoFrontier exploration, balancing multiple key indicators; simultaneously introducing manufacturability and scale-up constraints, pre-assessing expression systems and purification pathways, significantly reducing screening scale, and improving hit rates.

Combining Bluepha's experience in metabolic engineering and process scaling,Both parties will promote the R&D model to shift from "experience-driven" to "data+"Algorithm-Driven" Transformation, the model accuracy will be gradually improved through prior screening and continuous learning, achieving a synergistic optimization of cost, quality, and cycle. In the application of bio-based material products, both parties will iterate algorithms with real data feedback, using an engineering approach of rapid incremental progress to accumulate industry priors and evaluation benchmarks, accelerating the discovery and industrialization of high-performance enzymes and materials.

Looking to the future, BioMap and Beijing Bluepha Microbiology Technology Co., Ltd. will continue to deepen the construction of intelligent R&D platforms and expandAIThe application boundaries in each环节 of biomanufacturing.Focusing on底层通用酶与关键通路蛋白, the two parties will jointly build standardized datasets and validation processes,打通算法、工艺与产线之间的数据接口, forming a sustainably evolving "model".—Process—"Production Line" Community. By leveraging large models for prior analysis and experiments for validation, a new generation of intelligent R&D platforms for bio-based materials will also drive bio-manufacturing into a new phase of high-quality growth in a more predictable, reproducible, and scalable manner. Both parties look forward to collaborating with more research institutions, industry partners, and upstream and downstream enterprises to build an open, trustworthy, and win-win ecosystem.AIEmpower green manufacturing and accelerate the comprehensive upgrade of green and sustainable manufacturing.

About Bluepha Microbiology

Bluepha Microbiology was founded in2016Year10Month, a global leader in industrial and consumer biotechnology, is a national-level high-tech enterprise, a unicorn in bio-manufacturing, and a key national R&D program undertaking unit, with its headquarters located in Hongkou District, Shanghai. The company's core R&D team comes from top domestic and international universities and research institutions such as Peking University, Tsinghua University, the Chinese Academy of Sciences, and Harvard Medical School. It has independently built an industry-leading synthetic biology high-throughput automated R&D innovation platform, achieving an average...6Months from lab to market with rapid delivery, shortening the industry average cycle.70%; producing more than a hundred scientific and technological achievements, including invention patents, and completing“BioHybrid”The industrialization and implementation of multiple industry-first technologies and processes have been widely reported by media outlets such as CCTV, Xinhua News Agency, Liberation Daily, and Wen Wei Po.

Bluepha Microbiology Technology Co., Ltd. analyzes and designs biological processes at the genetic level using synthetic biology technology to create bio-based products for industrial and consumer applications. It empowers green and high-quality development in agriculture, consumer goods, environmental protection, healthcare, and other industries. Successfully, it has achieved industrial-scale implementation of new raw materials across multiple sectors, including biomaterials and bioactive compounds, consumer goods and services, agricultural biotechnology, and alternative proteins.